激素受体阳性/人表皮生长因子受体2阴性晚期乳腺癌二线内分泌治疗联合或不联合哌柏西利再挑战:PALMIRA试验
PALMIRA是一项国际随机开放标签II期研究,纳入198例一线哌柏西利联合内分泌治疗后进展的激素受体阳性/HER2阴性晚期乳腺癌患者,按2:1随机接受哌柏西利再挑战联合二线内分泌治疗或单纯二线内分泌治疗。结果显示中位无进展生存期分别为4.9个月和3.6个月(HR 0.84,95%CI 0.66-1.07,P=0.149),差异无统计学显著,哌柏西利联合组≥3级治疗中出现的不良事件发生率更高(47.4% vs 10.0%)。
要点
- 哌柏西利再挑战联合二线内分泌治疗未显著改善无进展生存期(HR 0.84,95%CI 0.66-1.07,P=0.149)。
- 中位无进展生存期哌柏西利联合组4.9个月 vs 单纯内分泌治疗组3.6个月。
- ≥3级治疗中出现的不良事件发生率哌柏西利联合组47.4% vs 单纯内分泌治疗组10.0%。
核心结论
- 在一线哌柏西利联合内分泌治疗进展的激素受体阳性/HER2阴性晚期乳腺癌患者中,哌柏西利再挑战联合替代内分泌治疗相比单纯内分泌治疗未显著改善无进展生存期。
研究设计与样本
- 国际、随机、开放标签、II期研究,纳入198例一线哌柏西利联合内分泌治疗(芳香化酶抑制剂或氟维司群)后进展的激素受体阳性/HER2阴性晚期乳腺癌患者,按2:1随机分配至哌柏西利再挑战联合二线内分泌治疗(氟维司群或来曲唑)组或单纯二线内分泌治疗组,分层因素为既往内分泌治疗和内脏转移。
主要发现
- 2019年4月至2022年10月间,136例和62例患者分别随机分配至哌柏西利联合内分泌治疗组和单纯内分泌治疗组。
- 研究者评估的中位无进展生存期哌柏西利联合内分泌治疗组为4.9个月(95%CI 3.6-6.1),单纯内分泌治疗组为3.6个月(95%CI 2.5-4.2),风险比0.84(95%CI 0.66-1.07;P=0.149)。
- ≥3级治疗中出现的不良事件发生率哌柏西利联合内分泌治疗组为47.4%,单纯内分泌治疗组为10.0%,未观察到新的安全性信号。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors plus endocrine therapy (ET) represents the standard first-line treatment for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HER2-negative) advanced breast cancer (ABC). However, there is no definitive consensus on the preferred second-line treatment option. The PALMIRA trial investigated whether palbociclib rechallenge with an alternative ET would improve the antitumor activity in patients progressing after a first-line palbociclib-containing regimen. METHODS: This international, randomized, open-label, phase II study enrolled 198 patients with hormone receptor-positive/HER2-negative ABC with disease progression after first-line palbociclib plus ET (aromatase inhibitor or fulvestrant). Patients were eligible if they showed clinical benefit to the previous regimen (response or stable disease ≥24 weeks) or had progressed on a palbociclib-based therapy in the adjuvant setting. Patients were randomly assigned (2:1 ratio) to either palbociclib rechallenge plus second-line ET (fulvestrant or letrozole) or second-line ET alone. Stratification factors were previous ET and visceral involvement. The primary end point was investigator-assessed progression-free survival (PFS). RESULTS: Between April 2019 and October 2022, 136 and 62 patients were randomly assigned to palbociclib plus ET or ET alone, respectively. Median investigator-assessed PFS was 4.9 months (95% CI, 3.6 to 6.1) with palbociclib plus ET versus 3.6 months (95% CI, 2.5 to 4.2) with ET alone (hazard ratio, 0.84 [95% CI, 0.66 to 1.07]; P = .149). Grade ≥3 treatment-emergent adverse events were higher with palbociclib plus ET (47.4% v 10.0%), without new safety signals. CONCLUSION: Palbociclib rechallenge plus an alternative ET did not significantly improve PFS compared with ET alone in patients with hormone receptor-positive/HER2-negative ABC progressing on a first-line palbociclib-based ET regimen.
引用
- Llombart-Cussac A, Harper-Wynne C, Perelló A, et al. Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial. J Clin Oncol. 2025. PMID: 40294349. doi:10.1200/JCO-24-01865
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。